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The symbiotic gut microbiota modulate health and disease of the host through a series of transgenomic
metabolic and immune regulatory axes. We explore connections between microbiome composition and
function related to individual metabolic phenotypes and consider these interactions as possible targets for
developing new personalized therapies and clinical management strategies.The relationship between the degree of gut health and human
disease processes has long been recognized: Hippocrates
(460–370 B.C.) stated,‘‘All diseases begin in the gut.’’ The inti-
mate coevolution of the microbiota with their mammalian hosts
has resulted in an interlocked symbiotic relationship with the
microbiota controlling or contributing to essential host functions
such as harvesting energy, shaping the host immune system,
metabolism of xenobiotics, and metabolic signaling (Hooper
et al., 2012). Historically, research into host-microbial interac-
tions has been limited by difficulties in culturingmost of the intes-
tinal bacteria due to their requirement for strict anaerobic condi-
tions or dependency upon other bacterial species. However,
recent development of culture-independent genomic methods
for characterizing the gut microbiota has prompted a resurgence
in interest in the contribution of themicrobiota to disease etiology
and, for example, the sequencing of more than 3.3million human
gut bacterial genes in 124 Europeans, which suggests that the
communal gut microbial genome or microbiome is at least 150
times larger than that of the human host (Qin et al., 2010).
The concept of the mammalian supraorganism, with the gut
microbiota collectively acting as a major virtual organ that
augments host metabolism and physiology, has resulted in
a paradigm shift in understanding human biology and medicine.
Coevolution of the microbiome with the host is such that many
bacterial symbionts carry a reduced genome and lack genes
that are essential in other bacteria (McCutcheon and Moran,
2010), while many of the genes they retain directly benefit the
host at little or no benefit to the bacterium (McCutcheon and
Moran, 2010; Xu and Gordon, 2003). For example, Bacteroides
thetaiotamicron can initiate development of the intestinal submu-
cosal capillary network via stimulation of Paneth cells in the
epithelial crypt to secrete angiogenins (Xu and Gordon, 2003).
Thus, the microbiome collectively provides critical biosynthetic
pathways that significantly extend host metabolic capacity.
The Contribution of the Microbiota to Individual
Phenotypes
Babies develop their microbiome at or before birth, and expo-
sure to bacteria through the vaginal birth canal—or contactwith maternal skin in the case of Caesarian born babies—trans-
fers at least some portion of thematernal microbiome to the baby
(Costello et al., 2012). This primary ‘‘seed’’ microbiota is subse-
quently modulated by a myriad of environmental, genetic, and
epigenetic factors that together shape the uniquemicrobial land-
scape within an individual. The gut microbial composition in the
newborn undergoes substantial modulation with sequential
waves of opportunistic microbes in an ecological succession,
taking residence to ultimately form a predominantly anaerobic
microbial community (clostridia, bifidobacteria, bacteroides) in
the gut luminal habitat within the first few days after birth (Cost-
ello et al., 2012). Observations in germ-free animals exposed to
the environment mirror this dynamic evolution of the infant
microbiome in early colonization, and functionally this is re-
flected in a series of compositional changes in the biofluids
and tissues (Holmes et al., 2012), with urine profiles exhibiting
a succession of phenolic compounds such as 2- and 3-hydrox-
yphenylpropionate, phenylacetylglycine, and hippurate stabi-
lizing around 3 weeks after primary environmental exposure.
Similar biochemical sequelae occur after antibiotic administra-
tion. Colonization of germ-free rodent and pig models with
human baby microbiota has allowed investigation of the impact
of various nutritional strategies in shaping the stable adult micro-
biota. However, extrapolation from rodent models to humans is
nontrivial, in that xenobiotic-metabolizing enzymes, such as
cytosolic glutathione-S-transferase, can have markedly different
metabolizing capacity in human microbiota compared to rodent
microbiota (Lhoste et al., 2003).
The diversity of the microbiome alters across body sites,
between people, and with age and is diet-dependent, resulting
in a series of unique habitats within and between individuals
that are subject to temporal variation and variation between pop-
ulations (Costello et al., 2012, Yatsunenko et al., 2012). However,
although interindividual variability in microbial composition is
amazingly diverse; recent metatranscriptomic studies suggest
that many of these microbial genes that differ between individ-
uals may in fact be phenocopies and therefore capable of
carrying out the same functions for the host (Gosalbes et al.,
2012).Cell Metabolism 16, November 7, 2012 ª2012 Elsevier Inc. 559
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The question as to what constitutes a healthy microbiome
remains largely unanswered because of the uniqueness of the
microbiome of each individual, especially at the species and
strain level, although there are clearly communities at the family
and class levels that have been identified as consistent with gut
health (Holmes et al., 2012). An increasing number of studies are
being conducted to explore the composition and metabolic
capacity of the microbiomes of healthy individuals at various
stages of development and aging. The best-known axis for these
‘‘mammalian-microbial interactions’’ is the mucosal immune
system, distributed throughout the length of the gastrointestinal
tract and othermucosal surfaces. Themicrobiota are essential to
appropriate development of a mature immune system, and
germ-free animals are known to have aberrant lymphoid tissue
and T and B cell subsets (Hooper et al., 2012). The microbiota
can exert an influence on the innate immune system by interact-
ing with toll-like receptors (TLRs), whose basic purpose is to
detect invading pathogens. TLR2 and TLR4 are thought to
recognize lipopolysaccharide and peptidoglycan, respectively,
and the activation of these receptors results in production of
cytokines and chemokines to protect against pathogenic
bacteria (Brown et al., 2011). However, activation of proinflam-
matory pathways by TLR2 is associated with genetic inflamma-
tory diseases (Hooper et al., 2012). Furthermore, TLR2-deficient
mice develop insulin resistance, a phenomenon that is associ-
ated with an increase in Firmicutes and that can be reversed
by the administration of antibiotics (Hooper et al., 2012). Interest-
ingly, TLR2-deficient germ-free mice do not develop insulin
resistance, although the fact that other groups do not report
this phenomenon would suggest that the expression of
the insulin-resistant phenotype is multifactorial. Although the
primary function of the TLRs within the mucosal layer is to iden-
tify and eliminate pathogenic bacteria, the commensal bacte-
rium Bacteroides fragilis can suppress rather than initiate inflam-
mation by signaling via a polysaccharide factor through murine
TLR2 in Foxp3(+) regulatory T cells, allowing the bacterium to
colonize a uniquemucosal niche (Round et al., 2011); the authors
conclude that the mucosal receptor can distinguish between
symbiotic and harmful bacteria. Another example is the ob-
servation that development of diabetes in the nonobese diabetic
(NOD) mouse, lacking the myeloid differentiation factor (MyD88),
is dependent upon colonization with microbiota to develop
protection against diabetes (Hooper et al., 2012).
In addition to the close communication between the micro-
biome and the host immune system, several other communica-
tion axes exist (Figure 1A) involving exchange between the gut
and other organs via neurotransmitters, bile acids, short chain
fatty acids (SCFAs), choline degradation products, aromatic
acids and phenolics, inflammatory mediated lipids, and endo-
cannabinoids (Holmes et al., 2012, Muccioli et al., 2010). The
behavior of these interactive axes of host-microbial communica-
tion varies in any individual according to development stages
and local environmental conditions. Indeed, within an individual,
the same microbial products may—depending upon temporal
and topographical circumstances—achieve either a beneficial
or adverse effect.
A number of diverse diseases have been associated either
causally or consequentially with dysregulation of the gut micro-560 Cell Metabolism 16, November 7, 2012 ª2012 Elsevier Inc.biome including Crohn’s Disease, colon cancer, diabetes, meta-
bolic syndrome, cardiovascular disease, stress and anxiety,
food allergies, asthma, autism, hepatic encephalopathy, and
eczema (Nicholson et al., 2012). Studies in both animal models
and humans have shown that obese and lean individuals harbor
a different gut microbial composition, and several studies have
pointed to an increased Firmicute:Bacteroidetes ratio as being
one of the key signatures of obesity that can be modulated by
a weight reduction diet (Jumpertz et al., 2011). However, other
research groups have failed to find consistent differences in
either the Firmicutes or Bacteroidetes in the microbiota of obese
and nonobese individuals (e.g., Schwiertz et al., 2010), suggest-
ing that the relationship between metabolic syndrome, obesity,
nutrition, and the microbiota is complex and multifactorial. Irre-
spective of the exact relationship between the microbiota and
obesogenesis, it appears that body weight and obesity are asso-
ciated withmicrobial composition and can bemodulated by diet.
Serino and colleagues showed that in a dietary-induced obese
C57BI/6 mouse model, some mice developed a diabetic meta-
bolic phenotype despite having the same genetic background
and diet, while others were resistant and the diabetic metabolic
phenotype was associated with gut permeability and a modified
gut microbiota (Serino et al., 2012). Metabolic parallels can also
be drawnwhereby urinary, fecal, and plasma profiles from obese
and lean individuals differ, both in endogenous and in microbially
derived metabolite composition. Metabolites such as hippurate
and phenylacetylglutamine have been associated with leaner
phenotypes in animal models and in man (Holmes et al., 2011).
The transmissibility of beneficial and adverse microbiomes,
particularly with respect to the development of obesity and
insulin resistance, remains a controversial subject. In a study of
infants up to 6 months old, Collado and coworkers showed that
fecal Bacteroides spp., Staphylococcus spp., and Clostridium
difficile counts were higher in babies from overweight mothers
and that weight gain during pregnancy also impacted on the
microbial composition (Collado et al., 2010). Other studies
have suggested that properties of the maternal microbiome,
such as resistance to antibiotics, can also be transmitted to
the offspring. The tantalizing prospect that gut microbial diversity
is linked to obesity and metabolic syndrome—and that this rela-
tionship begins at, or even before, birth—merits further attention
and may promote the identification of biomarkers of metabolic
function and lead to the development of potential treatment
strategies.
Functional Metagenomics
In concert with the development of high-throughput sequencing
for characterizing the composition of the microbiome, new
methods for assessing the composite functionality of the micro-
biome are required. In reality, ‘‘Who’s there?’’ is less important
than knowing ‘‘Who is active?’’ and what their metabolic capa-
bility is with respect to influencing the host either structurally,
for example by modulating gut permeability, or functionally. In
addition, we are currently unable to say at what abundance
a function needs to be in order to make an impact. The function-
ality of microbes can be inferred either from sequence-based
screening of genes or by heterologous expression. Sequencing
of genes is rapid and effective but reliant upon homologies
in available databases. Application of 16S rRNA genes as
Figure 1. Metabolic Axes between Host and the Gut Microbiota
(A) Schematic showing some of the major metabolites involved in host-microbe communication, originating from synthesis frommicrobial conversion of nutrients
and host metabolites in the gut lumen and their subsequent transport and interaction with other organs throughout the body. Metabolic axes of host-microbe
communication include neurotransmitters such as 5-hydroxyindole and certain biogenic amines; short-chain fatty acids that contribute to energy metabolism in
a range of organs and tissues; branched chain amino acids; phospholipid metabolites and bacterial products of choline degradation, e.g, trimethylamine-N-
oxide, which has been associated with cardiovascular disease (Wang et al., 2011); triglycerides and fatty acids; microbiota-produced vitamins (e.g., vitamin K);
and cometabolites of phenolics and aromatic acids such as 4-cresyl sulfate and hippurate.
(B) The phylogenetic arrangement of members of the genera Prevotella, Bacteroides, and Escherichia/Shigella using the 16S rRNA gene as the taxonomic
discriminator.
(C) A principal component analysis of genomes from the Integrated Microbial Genomes database, using the COG functions to cluster the organisms. The three
clusters highlighted are those that include the Bacteroidetes and Prevotella (cluster 1); Enterobacteriaceae (cluster 2); and Firmcutes, Ruminococci, and
Actinobacteria (cluster 3).
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ential enrichment of bacterial populations under genetic and
dietary-induced models of obesity (Jumpertz et al., 2011). In-
depth sequencing from several studies has led to the identifica-
tion of carbohydrate active enzymes capable of breaking down
otherwise indigestible dietary fiber, and over 80 families of glyco-
side-hydrolases have been identified in the human gut micro-
biome (Moore et al., 2011).
An alternative strategy for assigning metabolic functionality to
the gut microbiota is to adopt a ‘‘top-down strategy’’ and screen
host biofluids/tissues for components of their chemical compo-
sition that originate from bacteria or other organisms rather than
from host metabolism. Analytical platforms such as high-resolu-
tion spectroscopy for metabolic profiling are being adapted formeasuring and quantifying gut microbially derived metabolites.
This approach has led to the association of some of the most
prominent microbial-related metabolites in urine (e.g., hippurate,
phenylacetylglutamine, 4-cresylsulfate, 4-hydroxyphenylpropio-
nate) with body weight in various animal models—and in blood
pressure and metabolic syndrome in both humans and animal
models (Nicholson et al., 2012).
Attempts at ‘‘Human Stratification’’ According to Their
Microbial Composition—The Enterotype Concept
Stratifying the human population into different genotypic groups
based on GWAS has been pursued to understand mechanisms
of disease and underlying genetic variation. To this end two
recent studies (Arumugam et al., 2011; Wu et al., 2011) haveCell Metabolism 16, November 7, 2012 ª2012 Elsevier Inc. 561
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composition of the bacterial species in the large intestine. In
the first study, Arumugam and coworkers used bioinformatic
clustering based on similarity measures of the whole communi-
ties and concluded that their test cohort could be split into three
groups, which they termed enterotypes. The three enterotype
clusters were putatively defined by an enrichment of members
of the Bacteroides, Prevotella, or Ruminococcus species clades.
In a follow-on study, Wu et al. (2011) concluded that only two en-
terotypes were strongly supported by new data and that
evidence for the Ruminococcus enterotype was lacking. Wu
explored the effect of high/low-fat diet on the enterotypes and
surmised that although changes in the microbiome were
apparent within 24 hr, diet failed to change the enterotype after
10 days. Although the enterotype concept is an attractive
hypothesis, the evidence is not compelling, and several studies
(e.g., Yatsunenko et al., 2012; Claesson et al., 2012) do not
strongly support this concept, which Arumugam et al. (2011)
showed to be independent of health status, age, BMI, location,
or gender. This stratification raises interesting questions: If the
human population can be separated into two or more entero-
types, are there other emergent phenotypes that may be due
to these clusters? And how do these enterotypes relate to meta-
bolic phenotypes (metabotypes), particularly with respect to the
opportunity for stratifying individuals or populations for disease
risk or intervention? Since we know that the gut microbiome
can influence the host’s metabolome (Nicholson et al., 2012), it
begs the question, ‘‘Is the gut bacterial stratification in the pop-
ulation reflected in a similar stratification of the population
metabolite pool?’’ Currently, neither the fecal nor urine metabo-
lomes show such levels of differentiation even though large pop-
ulation cohorts have been studied, and it should be noted that all
themetagenomic studies together only cover a few hundred indi-
viduals. This disconnect between the enterotypes and metabo-
types in the population raises further questions as to whether
the enterotypes are biologically or bioinformatically significant.
The validity of the model remains untested and will require
more data and further scrutiny of the bioinformatic methods to
ensure they are statistically robust. Analysis of the taxonomy of
the prevalent bacterial members of these two enterotypes shows
that these species are clearly differentiated into separate genus-
level clades when using the 16S rRNA gene (Figure 1B). Such
taxonomic separation, though, is misleading since at higher
taxonomic levels, for example the order level, both genera are
members of the same group, i.e., Bacteroidales. This shared
evolutionary history implies shared functions in the two genera,
and the genomedata back this view. Clustering of the twogenera
based on their functions (Figure 1C) results in a continuous and
overlapping functional group. Hence, this may explain why the
two enterotypes do not manifest as two distinct metabotypes,
since they are potentially providing the host with the same
general functions. To understand what change is required in
the gut microbiota to be reflected in the host, we need to
know, ‘‘By how much do we need to alter the gut microbiota in
order to see a shift in the host’s metabotype?’’ Diet, antibiotics,
pre-/probiotics, drugs, and surgery can all bring about ameasur-
able change in the gut microbial community. A dramatic shift in
the microbiota, such as that brought about by Roux-en-Y gastric
bypass (RYGB) surgery, from a Bacteroidetes/Firmicutes-562 Cell Metabolism 16, November 7, 2012 ª2012 Elsevier Inc.predominant community to an Enterobacteriaceae driven
community, is associated with a clear change in metabotype
(Li et al., 2011). Thus, if we cluster these taxonomic groups using
the functional sets of genes from their genomes, we see that the
Enterobacteriaceae cluster in a defined group away from the
Bacteroidales (Figure 1C) as do the Firmicutes. It appears that
we need to dramatically alter the balance of bacteria in the gut
in such a way as to shift it toward a radically functionally isolated
cluster (e.g., following RYGB) to influence the host’s metabo-
lome. Given that the metabolic progression toward obesity and
insulin resistance is continuous and can be relatively subtle
and slow, the enterotype may not be a useful concept unless
some measure of functionality can be incorporated.
Dietary Modulation of the Gut Microbiome
Dietary modulation of the microbiome has received much atten-
tion, and the literature abounds with contradictory reports on
the ability of dietary interventions such as pro- and prebiotic
administration to substantially alter the gut microbiome for any
extended period of time. Probiotics are live microorganisms
that are beneficial to the host, while prebiotics are substances
that can promote growth of beneficial bacteria, modulate immu-
noregulatory cells via TLRs and NOD receptors, and alter the
functionality of various metabolic pathways, including those
involved in carbohydrate metabolism (Holmes et al., 2012).
They have been shown to be efficacious in decreasing the inci-
dence of diarrhea and atopic eczema. Evaluation of the true
merits of pre- and probiotics—or combinations (synbiotics)
thereof—is severely hindered by poor clinical trial design, lack
of clarity on regulatory guidelines, and low participant numbers
in clinical trials. There is growing demand for better guidelines
and improved study design.
Increasing bodies of evidence show that both long- and short-
term dietary habits significantly modify the host microbial com-
munity and functions, thereby influencing host metabolism and
disease risk or development. This modification is reflected
both at the individual level and the population level. Microbiota
in Malawian and Amerindian infants are more similar to each
other than to those of American infants. As the microbiome
matures, overrepresentation of enzymes capable of degrading
proteins and simple sugars was found in the American adults,
while a-amylase, an enzyme required for starch breakdown,
was overrepresented in the Malawian and Amerindian micro-
biomes (Yatsunenko et al., 2012).
Both macronutrients and micronutrients are important in
shaping the gut microbial landscape. A choline-deficient diet
can be used to achieve fatty liver development, and research
has shown that gut bacteria can bemodulated by dietary choline
intake with altered levels of Gammaproteobacteria and Erysipe-
lotrichi (Spencer et al., 2011). Conversely, a diet supplemented
with either choline or trimethylamine-N-oxide in atheroscle-
rosis-pronemousemodel resulted in elevated levels of trimethyl-
amine-N-oxide in plasma, which correlated with the size of
atherosclerotic plaques, inferring a link between choline metab-
olism and the development of atherosclerosis (Wang et al.,
2011). This link was negated in animals in which the gut micro-
biota had been suppressed, further underscoring the tripartite
relationship between the gut microbiota, the diet, and host
metabolism. Gut microbial composition and function are also
Table 1. Impact of Various Interventions on the Gut Microbiota and Host Metabolism
Intervention Effect on Microbiota Effect on Metabolism
Antibiotics Target on pathogens
Affect microbial growth
Promote antibiotic-resistant strains
Change microbial diversity
Promote opportunistic pathogens
Reduced urinary and fecal microbial and
microbial-host metabolites such as indoles,
phenols, short chain fatty acids, etc.
Prebiotics Increase Bifidobacteria and Lactobacillus
population
Short-chain fatty acid production (butyrate,
propionate, and acetate)
Probiotics Balance gut microbial community Short-chain fatty acid production (butyrate,
propionate, and acetate)
Fiber Reversely associated with Bacteroides and
Actinobacteria and positively associated with
Firmicutes and Proteobaccteria
Short-chain fatty acid production (butyrate,
propionate and acetate)
Carbohydrates Negatively associated with Bacteroides and
positively associated with Prevotella
Involved in glycolysis
Glycans Higher prevalence of Bacteroidetes and some
species of the phyla Firmicutes and Actinobacteria
Short-chain fatty acid production (butyrate,
propionate, and acetate)
Fats Positively associated with Bacteroides and
Actinobacteria and negatively associated
with Firmicutes and Proteobaccteria
Switching mice to a western diet significantly
increased the Erysipelotrichi and significantly
decreased the Bacteroidetes
Milk fats promote delta Proteobacteria and
drive inflammation
Altered fatty acids and triglycerides
Altered bile salts
Choline-deficient diet Gammaproteobacteria higher in choline-
deficient diet.
Choline, betaine, sarcosine, phosphatidylcholine
decreased; homocysteine increased
Protein (amino acids and choline) Positively associated with Bacteroides and
negatively associated with Prevotella
Altered glucose homeostasis; increased
branched chain amino acids
Caloric restriction and malnutrition Shift in C. histolyticum, C. lituseburense, and
E. rectale-C. coccoides and Bacteroides-Prevotella
with weight loss
Higher percentage of proteobacteria in malnutrition
Perturbed TCA cycle intermediates, altered
hippurate production
Change in ACE2 leads to altered gut microbiota,
which are proinflammatory
Iron depletion Increased number of Lactobacilli and
Enterobacteriaceae, decreased Roseburia spp.
and E. rectal group
Lower cecal butyrate and propionate
GI surgery (e.g., RYGB) Promote growth of Gammaproteobacteria Altered host-microbial cometabolites and amines
Fecal transplant Restoration of normal gut microbial ecology
A brief summary of exemplar metabolic andmicrobial effects induced by various therapeutic and dietary interventions. Information taken fromWu et al.
(2011), Nicholson et al. (2012) Holmes et al. (2011), Dostal et al. (2012), Wang et al. (2011), Spencer et al. (2011), and Serino et al., 2012, among other
literature.
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example, iron-deficient rats have been shown to harbor mark-
edly lower levels of cecal short-chain fatty acids such as butyrate
and propionate in comparison with iron-sufficient animals,
together with increased population of Lactobacilli and Entero-
bacteriaceae and a depleted number of butyrate producers
such as Roseburia spp./E. rectal group (Dostal et al., 2012).
Thus, it is apparent that the relationship between the gut micro-
biota and host is exquisitely intricate and that understanding the
equilibriumbetween host andmicrobe requires the application of
a systems biology approach to establish the chemical and
genetic axes of communication if we attempt to influence this
relationship using personalized nutritional strategies. A summary
of selectedmicrobial, functional, andmetabolic effects of various
dietary and therapeutic interventions is provided in Table 1.Future Translational Goals: The TherapeuticModulation
of Gut Microbiome-Host Metabolic Axes
Themultiple axes of microbiome-host metabolic communication
and regulation offer up a series of potential targets for thera-
peutic interventions in a wide range of conditions including
obesity, inflammatory bowel, and cardiovascular diseases to
more controversial targets including neurobehavioral disorders
such as autism (Nicholson et al., 2012). The changing relation-
ships between the microbiome and host biochemistry during
development (Nicholson et al., 2012, Costello et al., 2012) also
offers a series of interventional windows that can be aligned
with disease prevention during early life and treatment in adults.
Interventions that target the microbiome range from the subtle
and usually temporary modulation of the microbiota by dietary
prebiotics, probiotics, or synbiotics through to more dramaticCell Metabolism 16, November 7, 2012 ª2012 Elsevier Inc. 563
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called fecal transplant, or bacteriotherapy. Much of the recent
work in this area has been undertaken by Thomas Borody,
who has shown conclusively that for certain patients fecal trans-
plantation can cure otherwise intractable ulcerative colitis and
colitis associated with persistent Clostridium difficile infections.
The microbiome itself has many potentially drugable targets,
i.e., modulation of microbial signaling activities to change host
metabolic regulation. This approach opens up new possibilities
for tailored or personalized healthcare paradigms wherein the
microbes themselves may represent drugable targets with the
opportunity for development of novel therapeutics. However,
to be effective this requires extensive biological knowledge of
these transgenomic processes, which is currently lacking.
Perhaps the greatest near-term opportunity with respect to ther-
apeutic targeting of the gut microbiota is the potential to exploit
the interindividual variation in microbial composition, which
contributes to differences in human metabolic phenotypes.
Thus, this variation need not be an insurmountable obstacle to
unraveling the complexity of host-microbial interplay with
respect to disease risk and etiology, but rather provides an
opportunity to place this variation within the framework of
a hierarchy of metabolic capability and function. Furthermore,
as it has been demonstrated that gut microbiota modulate
drug metabolic processes, there is value in understanding the
contribution of the microbiome to therapeutic variation to assist
in the generation of newmetrics of patient stratification (possibly
used in conjunction with more ‘‘traditional’’ genetic screening
processes) that can assist in optimizing therapies at a personal
level. Overall, microbiome research offers unparalleled new
insights into the pathogenesis and treatment of human diseases
and so is likely to have high translational value in future 21st
century healthcare paradigms.REFERENCES
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